Evaluating changes in radiation treatment volumes from post-operative to same-day planning MRI in High-grade gliomas

BackgroundAdjuvant radiation therapy (RT) with temozolomide (TMZ) is standard of care for high grade gliomas (HGG) patients. RT is commonly started 3 to 5 weeks after surgery. The deformation of the tumor bed and brain from surgery to RT is poorly studied. This study examined the magnitude of volume change in the postoperative tumor bed and the potential impact of RT planning.Method and materialsThis study includes 24 patients with HGG who underwent craniotomy and adjuvant RT with TMZ at our institution. All patients had immediate postoperative MRI and repeat MRI during the day of RT simulation. Gross tumor volumes (GTV), clinical target volumes (CTV) of initial 46 Gy (CTV1) and boost to 60 Gy (CTV2) were contoured on both sets of MRIs according to RTOG (Radiation Therapy Oncology Group) guidelines. For patients who recurred after RT, the recurrence pattern was evaluated.ResultsAn average of 17 days elapsed between immediate and delayed MRIs. GTV1 (FLAIR abnormality and tumor bed) decreased significantly on the delayed MRI as compared to immediate post-operative MRI (mean = 30.96cc, p = 0.0005), while GTV2 (contrast-enhanced T1 abnormality and tumor bed) underwent a non-significant increase (mean = 6.82cc, p = 0.07). Such changes lead to significant decrease of CTV1 (mean decrease is 113.9cc, p<0.01), and significant increase of CTV2 (mean increase is 32.5cc, p=0.05). At a median follow-up of 13 months, 16 patients (67%) progressed, recurred, or died, with a progression-free survival time of 13.7 months. Twelve patients failed within all CTVs based on immediate and delayed MRIs, while one patient recurred outside of CTV2 based on immediate post-operative MRI, but within the CTV2 defined on delayed MRI.ConclusionThe postoperative tumor bed of HGGs undergoes substantial volumetric changes after surgery. Treatment planning based on delayed MRI significantly reduces the volume of treated brain tissue without local control detriment. The marked reduction of volume treated to 46 Gy based on delayed MRI scan, could result in increased sparing of organs at risk. There may be a small risk of inadequate radiation field design if radiation planning is based on immediate post-operative MRI.

[1]  J. Cairncross,et al.  Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Shukla,et al.  T2 weighted MRI in assessment of volume changes during radiotherapy of high grade gliomas. , 2005, Journal of cancer research and therapeutics.

[3]  T. Chenevert,et al.  Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: Implications for conformal dose-escalation studies. , 2005, International journal of radiation oncology, biology, physics.

[4]  Robert G. Selker,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma , 2009 .

[5]  S B Green,et al.  Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. , 1989, Journal of neurosurgery.

[6]  K. Aldape,et al.  RADIATION THERAPY ONCOLOGY GROUP RTOG 0825 PHASE III DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE PLUS BEVACIZUMAB VERSUS CONVENTIONAL CONCURRENT CHEMORADIATION AND ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA , 2009 .

[7]  M. Berger,et al.  GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.

[8]  W. Curran,et al.  Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. , 2009, International journal of radiation oncology, biology, physics.

[9]  W. Yung,et al.  Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  M. Castillo Contrast enhancement in primary tumors of the brain and spinal cord. , 1994, Neuroimaging clinics of North America.

[11]  R. Bronen,et al.  Magnetic resonance imaging contrast agents: theory and application to the central nervous system. , 1990, Journal of neurosurgery.

[12]  U Oppitz,et al.  3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  K. Wallner,et al.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. , 1989, International journal of radiation oncology, biology, physics.

[14]  Shiao Y. Woo,et al.  Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. , 2007, International journal of radiation oncology, biology, physics.

[15]  M. Mehta,et al.  The Impact of Mid-Treatment MRI on Defining Boost Volumes in the Radiation Treatment of Glioblastoma Multiforme , 2004, Technology in cancer research & treatment.

[16]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[17]  Benedick A Fraass,et al.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Dillon Imaging of central nervous system tumors. , 1991, Current opinion in radiology.

[19]  T 2 weighted MRI in assessment of volume changes during radiotherapy of high grade gliomas , 2006 .

[20]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[21]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. , 2013, Neuro-oncology.